Early Reduction in Ambulatory Pulmonary Artery Pressures After Initiation of Sacubitril/Valsartan

Circ Heart Fail. 2021 Jul;14(7):e008212. doi: 10.1161/CIRCHEARTFAILURE.120.008212. Epub 2021 Jul 12.

Authors

Affiliations

¹ Brigham and Women's Hospital, Boston, MA (A.S.D.).
² Scripps Clinic, La Jolla, CA (J.T.H.).
³ The Heart Group of Lancaster General Health, Lancaster, PA (L.R.).
⁴ Ohio State University, Columbus (W.T.A.).
⁵ Abbott Labs, Austin, TX (P.A., M.-E.B., P.S.).
⁶ Advocate Medical Group, Downers Grove, IL (M.R.C.).
⁷ First Coast Cardiovascular Institute, Jacksonville, FL (S.L.).
⁸ Advent Health Transplant Institute, Orlando, FL (N.R.).
⁹ University of Southern California, Los Angeles, CA (D.S.).
¹⁰ Vanderbilt University Medical Center, Nashville, TN (L.W.S.).

PMID: 34247518
DOI: 10.1161/CIRCHEARTFAILURE.120.008212

No abstract available

Keywords: enalapril; heart failure; hemodynamic monitoring; neprilysin; pulmonary artery.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aminobutyrates / pharmacology*
Angiotensin Receptor Antagonists / pharmacology
Biphenyl Compounds / pharmacology*
Drug Combinations
Heart Failure / drug therapy*
Humans
Pulmonary Artery / drug effects*
Stroke Volume
Valsartan / pharmacology*

Substances

Aminobutyrates
Angiotensin Receptor Antagonists
Biphenyl Compounds
Drug Combinations
sacubitril
Valsartan
sacubitril and valsartan sodium hydrate drug combination